Empirical Antitubercular Treatment for Lymphadenopathy: Are We Missing Lymphoma?

Indian J Pediatr. 2023 Aug;90(8):761-765. doi: 10.1007/s12098-022-04180-6. Epub 2022 Jun 23.

Abstract

Objective: To evaluate the proportion of patients who received empirical treatment with antitubercular therapy (ATT) prior to the diagnosis of Hodgkin lymphoma (HL) in the first multicentric, prospective study on HL from India, and to assess its impact on extent of disease at diagnosis and outcomes.

Methods: Children < 18 y with biopsy proven HL were enrolled in InPOG-HL-15-01. Along with other clinical and epidemiological data, history of prior treatment with ATT was documented. All patients received treatment as per a risk-stratified, response-adapted strategy.

Results: Out of 396, 115 (29%) children had received ATT prior to establishing a definitive diagnosis of HL. This cohort presented with advanced-stage disease (p = 0.001) and B symptoms (p = 0.001) in a higher proportion of cases. Consequently, those children were more likely to receive 6 rather than 4 cycles of chemotherapy (p = 0.001). They were more likely to have infradiaphragmatic involvement (p = 0.001). Overall survival and event-free survival were not different.

Conclusion: Empirical treatment with ATT in children presenting with lymphadenopathy continues to be practiced widely in India. The delay in diagnosis may contribute to children presenting with advanced-stage disease warranting more intensive treatment for successful outcomes.

Keywords: Delayed diagnosis; Hodgkin lymphoma; Treatment burden; Tuberculosis.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Antitubercular Agents / therapeutic use
  • Child
  • Hodgkin Disease* / diagnosis
  • Hodgkin Disease* / drug therapy
  • Humans
  • Lymphadenopathy* / drug therapy
  • Prospective Studies

Substances

  • Antitubercular Agents